Literature DB >> 33668888

Idazoxan and Efaroxan Potentiate the Endurance Performances and the Antioxidant Activity of Ephedrine in Rats.

Gabriela Rusu-Zota1, Alexandra Burlui2, Elena Rezus2, Luminita Paduraru3, Victorita Sorodoc4.   

Abstract

Background and objectives: The connections between the imidazoline system and multiple other neurotransmitter systems in the brain (adrenergic, dopaminergic, serotoninergic, glutamatergic, opioid) indicate the complexity of the mechanisms underlying motor activity and behavior. The aim of the present research was to investigate the effects of the combination of ephedrine (EPD) and imidazoline antagonists idazoxan (IDZ) and efaroxan (EFR) on the endurance performance in the treadmill test in rats. Materials and
Methods: We used Wistar rats distributed as follows: Group 1 (Control) receiving distilled water 0.3 mL/100 g body weight; Group 2 (EPD) receiving 20 mg/kg ephedrine; Group 3 (EPD + IDZ) receiving 20 mg/kg ephedrine + 3 mg/kg idazoxan; Group 4 (EPD + EFR) receiving 20 mg/kg ephedrine + 1 mg/kg efaroxan. An additional group (C) of animals receiving 0.3 mL/100 g body weight distilled water (but not subjected) to effort was used. Endurance capacity was evaluated using a treadmill running PanLAB assay. The evaluation of the substances' influence on oxidative stress was performed by spectrophotometric determination of superoxide dismutase (SOD) and glutathione peroxidase (GPX) activity.
Results: Treatment with EPD-IDZ and EPD-EFR were correlated with a longer distance traveled on the belt and with a decrease in the necessary electric shocks to motivate the animal to continue running in the forced locomotion test. Additionally, an increase in the activity of antioxidant enzymes was found. Conclusions: Idazoxan and efaroxan potentiated the physical effort-related effects of ephedrine with regard to endurance capacity and antioxidant activity in rats.

Entities:  

Keywords:  efaroxan; endurance; ephedrine; exercise; idazoxan; imidazoline; oxidative stress

Year:  2021        PMID: 33668888      PMCID: PMC7996498          DOI: 10.3390/medicina57030194

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  38 in total

Review 1.  Classic animal models of Parkinson's disease: a historical perspective.

Authors:  Adjia Hamadjida; Imane Frouni; Cynthia Kwan; Philippe Huot
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

2.  Up-regulation of HIF-1α is associated with neuroprotective effects of agmatine against rotenone-induced toxicity in differentiated SH-SY5Y cells.

Authors:  Nadia Ferlazzo; Monica Currò; Maria Laura Giunta; Domenico Longo; Valentina Rizzo; Daniela Caccamo; Riccardo Ientile
Journal:  Amino Acids       Date:  2019-07-10       Impact factor: 3.520

3.  Protective effects of agmatine on doxorubicin-induced chronic cardiotoxicity in rat.

Authors:  Fatemeh Yarmohmmadi; Nastaran Rahimi; Hedyeh Faghir-Ghanesefat; Nina Javadian; Alireza Abdollahi; Parvin Pasalar; Farahnaz Jazayeri; Shahram Ejtemaeemehr; Ahmad Reza Dehpour
Journal:  Eur J Pharmacol       Date:  2016-12-16       Impact factor: 4.432

4.  Imidazoline binding sites mediates anticompulsive-like effect of agmatine in marble-burying behavior in mice.

Authors:  Madhura P Dixit; Prajwal P Thakre; Akshay S Pannase; Manish M Aglawe; Brijesh G Taksande; Nandkishor R Kotagale
Journal:  Eur J Pharmacol       Date:  2014-03-19       Impact factor: 4.432

Review 5.  Glutathione peroxidases.

Authors:  Regina Brigelius-Flohé; Matilde Maiorino
Journal:  Biochim Biophys Acta       Date:  2012-11-29

6.  Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease.

Authors:  Nazanin Mirzaei; Bibiana C Mota; Amy M Birch; Nicola Davis; Carmen Romero-Molina; Loukia Katsouri; Emily O C Palmer; Arantxa Golbano; Laura J Riggall; Istvan Nagy; Robin Tyacke; David J Nutt; Magdalena Sastre
Journal:  Br J Pharmacol       Date:  2020-12-27       Impact factor: 8.739

Review 7.  Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation.

Authors:  Bruno Lima Giacobbo; Janine Doorduin; Hans C Klein; Rudi A J O Dierckx; Elke Bromberg; Erik F J de Vries
Journal:  Mol Neurobiol       Date:  2018-08-17       Impact factor: 5.590

Review 8.  Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease.

Authors:  Eoin O'Neill; Andrew Harkin
Journal:  Neural Regen Res       Date:  2018-08       Impact factor: 5.135

Review 9.  Nitrosative Stress and Its Association with Cardiometabolic Disorders.

Authors:  Israel Pérez-Torres; Linaloe Manzano-Pech; María Esther Rubio-Ruíz; María Elena Soto; Verónica Guarner-Lans
Journal:  Molecules       Date:  2020-05-31       Impact factor: 4.411

Review 10.  Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer's Disease.

Authors:  Raluca Stefanescu; Gabriela Dumitriṭa Stanciu; Andrei Luca; Luminita Paduraru; Bogdan-Ionel Tamba
Journal:  Biomolecules       Date:  2020-06-06
View more
  1 in total

1.  Effects of imidazoline agents in a rat conditioned place preference model of addiction.

Authors:  V Şorodoc; G Rusu-Zota; P Nechita; C Moraru; O M Manole
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-08       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.